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ABSTRACT 
Background 
Varenicline and bupropion are effective smoking cessation treatments, but there are 
concerns about their safety in smokers with chronic obstructive pulmonary disease (COPD). 
We sought to investigate whether the two drugs are associated with serious adverse 
cardiovascular and neuropsychiatric events in smokers with COPD.  
  
Methods 
In a retrospective cohort study, we used data from 14,350 COPD patients included in the 
QResearch® database, which holds data from 753 National Health Service general practices 
across England. We identified COPD patients who received a prescription of nicotine 
replacement therapy (NRT; N=10,426; reference group), bupropion (N=350), or varenicline 
(N=3,574) in the period between January 2007 and June 2012. Patients were followed-up 
for six months to compare incident cardiovascular (i.e., ischaemic heart disease, cerebral 
infarctionstroke, heart failure, peripheral vascular disease, and cardiac arrhythmias) and 
neuropsychiatric (i.e., depression and self-harm) events using Cox proportional hazards 
models, adjusted for potential confounders. Propensity score analysis was used as an 
additional approach to account for potential confounding by indication. We also modelled 
the effects of possible unmeasured confounders.  
 
Findings 
Neither bupropion nor varenicline showed an increased risk of adverse events compared 
with NRT. Varenicline was associated with a significantly reduced risk of heart failure 
(HR=0.56, 95%CI=0.34-0.92) and depression (HR=0.73, 95%CI=0.613-0.86). Similar results 
were obtained from the propensity score analysis. Modelling of unmeasured confounding 
provided additional evidence that an increased risk of these adverse events was very 
unlikely.  
 
Interpretation 
In smokers with COPD, varenicline and bupropion do not appear to be associated with an 
increased risk of cardiovascular events, depression or self-harm when compared with NRT.  
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WHAT IS THE KEY QUESTION? 
Are varenicline or bupropion associated with an increased risk of serious cardiovascular 
events, depression or self-harm in smokers with COPD?  
 
WHAT IS THE BOTTOM LINE? 
In smokers with COPD, varenicline and bupropion do not appear to be associated with an 
increased risk of documented cardiovascular events, depression or self-harm.  
 
WHY READ ON? 
This is the first study investigating the most important serious neuropsychiatric and 
cardiovascular adverse events in one study and with the same rigorous methodology in a 
large sample (N=14,350) of COPD patients using real-life data. 
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INTRODUCTION  
Varenicline and bupropion are effective smoking cessation treatments, but have been 
suspected to be associated with serious adverse cardiovascular and neuropsychiatric events. 
The two drugs are proven to be effective in aiding long-term smoking cessation, both in the 
general smoking population [1, 2] and in the subgroup of smokers with chronic obstructive 
pulmonary disease (COPD).[3] However, post-marketing reports raised concerns about the 
risk of serious adverse cardiovascular and neuropsychiatric events, prompting the US Food 
and Drug Administration (FDA) and the European Medicines Agency (EMA) to add warnings 
in the drugs' prescribing information. This included a Boxed Warning – FDA’s most 
prominent warning – in the drug labels in 2009 regarding symptoms like depressed mood, 
suicidal thoughts and behaviour, and attempted suicide.[4]  
 
Very recently, the FDA decided to remove the Boxed Waring for serious mental health 
effects from the varenicline and bupropion labels.[5] This decision was based on a large 
randomised controlled trial that the FDA required the drug companies to conduct, which 
showed no significant increase in neuropsychiatric events in users of varenicline or 
bupropion compared with users of nicotine patch or placebo.[6] The trial thereby confirmed 
evidence from meta-analyses of previous randomised controlled trials and from 
observational studies indicating that a causal relationship between the use of these drugs 
and serious adverse cardiovascular and neuropsychiatric events is unlikely.[7-11] One of 
these studies was an observational study we conducted using analysis of a large, validated 
English primary care database.[11] 
 
Whereas there is now good evidence about the safety of varenicline and bupropion in the 
general smoking population, it is important to assess specifically whether these drugs are 
associated with serious adverse events in diseased subgroups, particularly in smokers with 
COPD who are already, by virtue of their diagnosis, at increased risk of cardiovascular and 
neuropsychiatric events.[12] Tobacco smoking is the most important risk factor for the 
development and progression of COPD,[13, 14] and smoking cessation is the only treatment 
with proven effectiveness to reduce the accelerated decline in lung function.[13, 14] It also 
effects other outcomes positively, for example the response to treatment with 
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bronchodilators and inhaled corticosteroids.[14] International guidelines therefore 
recommend that smokers with COPD should be assisted during their quit attempt with a 
combination of pharmacotherapy and behavioural support.[13, 15] In UK and German 
primary care, varenicline is the preferred pharmacotherapy in smokers with COPD.[16, 17] 
 
In our previous study,[11] we showed that varenicline and bupropion were not associated 
with an increased risk of serious adverse cardiovascular and neuropsychiatric events in the 
general smoking population. The aim of the current study, as detailed in our a priori 
published  study protocol,[18] was to investigate the safety of the two drugs in the subgroup 
of smokers with COPD.  
 
METHODS 
We conducted a national, retrospective cohort study using the QResearch® database 
(version 36, upload 31 July 2013), which holds anonymised health records on over 13 million 
patients from 753 National Health Service general practices from across England 
(www.qresearch.org). QResearch® has been used for various studies of the incidence and 
risk of neuropsychiatric and cardiovascular events, in particular our previous study on the 
safety of varenicline and bupropion in the general smoking population.[11] We have now 
used this database to investigate the risk of the two drugs in the subgroup of smokers with 
COPD – a specific aim we described earlier in our study protocol.[18] Whereas that protocol 
provides a detailed description of our analysis plan, we present an overview of our methods 
below. The only deviation from our published plan is that we could not perform an 
instrumental variable analysis because we were unable to identify a valid instrumental 
variable and that we instead, undertook additional analyses (i.e., modelling) to assess the 
impact of any potential unmeasured confounding. The use of this particular method was 
also prompted by concerns recently raised by the FDA in relation to evidence from previous 
observational studies on the safety of varenicline.[19]  
 
Inclusion and exclusion criteria 
We studied adult patients with recorded COPD who received prescriptions for varenicline, 
bupropion, or nicotine replacement therapy (NRT) between 1 January 2007 and 30 June 
2012. COPD was defined by appropriate Read codes (a clinical coding system used by 
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general practitioners in the UK; see[18]). Patients aged <35 years and with no recording of 
spirometry or Medical Research Council dyspnoea score[20] were excluded (14.0% of all 
patients with recorded COPD). The date of first prescription of one of these drugs defined 
the individual's entry date to the cohort. Patients were excluded if they had used one of the 
drugs during 12 months prior to the start date of the study or if they had received a 
prescription of a combination of these drugs during the follow-up period.   
 
Exposure measures 
Patients were categorised into three exposure groups: (1) varenicline alone, (2) bupropion 
alone, or (3) NRT alone, based on the drug they were first prescribed. . (We used NRT as a 
reference group to reduce the risk of confounding by indication[18] and because used as a 
reference group as it is presumed by regulators not to carry serious risks.) based on the drug 
they were first prescribed. In the UK, all three drugs are only licensed for use to aid smoking 
cessation.[21] Start of follow-up began for each patient on the date of the first prescription 
and ended after six months follow-up or when reaching the specific event of interest (see 
below). Patients who were lost to follow-up because they left the practice or died were 
censored on that date.  
 
Outcome measures 
We separately considered major incident neuropsychiatric and cardiovascular events that 
occurred during six months of follow-up for which a potential association with varenicline 
use has been suggested.[22-24] The cardiovascular events of interest were: ischaemic heart 
disease, cerebral infarctionstroke, heart failure, peripheral vascular disease, and cardiac 
arrhythmias. The neuropsychiatric outcomes of interest were: depression, and fatal or non-
fatal self-harm. A follow-up period of six months covers the treatment duration of the drugs 
(typically 12 weeks) as well as an extended period following termination of treatment in 
which many of the spontaneously reported adverse events occurred and where the excess 
in cardiovascular events was found in meta-analyses of clinical trials. As a secondary 
outcome, we assessed the occurrence of these events during the first three months of 
follow-up. 
 
Confounding factors  
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The following variables, measured at or prior to the patient's entry date to the cohort, were 
included in the analyses as potential confounders: age, sex, socio-economic status 
(measured using the Townsend Index[25]), Medical Research Council dyspnoea score[20], 
Strategic Health Authority of the general practice, relevant comorbidities from the Charlson 
Index[26] (i.e., diabetes, peptic ulcer disease, renal disease, rheumatological disease, or 
cancer), and alcohol misuse. In addition, any recordings of the neuropsychiatric and 
cardiovascular events of interest that occurred prior to the patient's entry date to the 
cohort were also included. 
 
Statistical analyses 
We used Cox proportional hazards regression models to assess the association between 
exposure group and each of the above mentioned events, adjusted for all measured 
potential confounders (see above). All variables were entered as binary variables into the 
models except for the continuous variables age and socio-economic status. We also used a 
propensity score analysis with trimming and matching to account for potential confounding 
by indication (the methodological details of this analysis have been reported in our study 
protocol[18]). In addition, we used an approach described by Lin et al.[27] to model the 
effects of any potential unmeasured confounding. For this purpose, we adjusted the hazard 
ratios (HRs) and 95% CIs in users of varenicline versus NRT for each of the events for a 
hypothetical, unmeasured, binary confounder with a HR of three and various combinations 
of prevalence among the two exposure groups. 
 
All analyses were undertaken in R (Version 3.0.2 or later). We provide the codes used in R as 
supplementary material (supplementary Text E1). All statistical tests were two-sided with 
p<0.05 indicating significance. 
 
Ethical considerations 
This study involved the analysis of anonymised, routinely collected data. Our protocol was 
independently peer-reviewed by the QResearch® Scientific Board and satisfied the 
requirements of the Trent Research Ethics Committee. 
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RESULTS 
A total of 14,350 COPD patients were included in the analyses: 10,426 users of NRT, 350 
users of bupropion, and 3,574 users of varenicline (Figure 1). This subgroup of smokers with 
COPD from the database were older, more deprived, and showed higher prevalence rates of 
comorbid diseases, including the cardiovascular and neuropsychiatric diseases of interest, 
than the subgroup of smokers without COPD (Table 1).  
 
COPD patients who used NRT were older, had more severe dyspnoea, and showed higher 
prevalence rates of comorbid diseases than users of bupropion and varenicline (Table 2). 
The highest incidence rates of events were found for depression and ischaemic heart 
disease (Table 3, supplementary Figures E1-7). 
 
Cox proportional hazards regression analyses 
Neither bupropion nor varenicline showed an increased risk of any cardiovascular or 
neuropsychiatric event compared with NRT (Table 3). Only for ischaemic heart disease, the 
HR was higher than 1 in users of bupropion and varenicline, but this difference was not 
statistically significant (in case of varenicline, the HR was only minimally higher than 1, and 
the confidence interval was large: HR=1.02, 95%CI=0.83-1.24). Rather, varenicline was 
associated with a significantly reduced risk of heart failure (HR=0.56, 95%CI=0.34-0.92) and 
depression (HR=0.73, 95%CI=0.61-0.86). 
 
Chi-squared tests indicated that hazards were not proportional for the outcome depression 
(p=0.041), but a more fine-grained analysis allowing for varying HRs indicated that the HR 
always fell below 1.00 across the entire follow-up period. Thus, for this outcome the 
reported HR can be regarded as an average across the follow-up period. Furthermore, we 
found that the risk of heart failure in users of varenicline compared with NRT differed 
statistically between females and males (p=0.017), but the HR was again always below 1.00. 
 
Propensity score analyses  
After trimming and matching patients by propensity score, the sample size was 682 for the 
comparison of bupropion versus NRT, and 6,968 for the comparison of varenicline versus 
NRT. A comparison of patient characteristics showed that the drug groups were generally 
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well matched in both comparisons (supplementary Table E1). Neither bupropion nor 
varenicline showed an increased risk of any neuropsychiatric or cardiovascular event 
compared with NRT (Table 5).  
 
Modelling of unmeasured confounding 
The modelling showed that an increased risk of any of the neuropsychiatric and 
cardiovascular events in users of varenicline was very unlikely (supplementary Tables E2-8). 
For example, an unmeasured confounder with a HR of three for self-harm would have 
reversed the observed reduced HR in users of varenicline versus NRT (HR=0.78) into an 
increased HR (>1.00) only if the prevalence of this confounder had been distributed very 
differently among the two exposure groups of medication users (e.g., . For such an 
outcome, the prevalence of this confounder would need to be only 0% among users of 
varenicline and simultaneously be found in at least 90% among users of NRT; (Table 4). 
 
Secondary analyses 
The results from the Cox proportional hazards regression analyses, the propensity score 
analyses, and the modelling of unmeasured confounding with the occurrence of the 
cardiovascular and neuropsychiatric events during three months of follow-up yielded very 
similar results (supplementary Tables E9-17). 
 
DISCUSSION 
We found no evidence for any increased risk of cardiovascular and neuropsychiatric adverse 
events in smokers with COPD using varenicline or bupropion to aid their quit attempt when 
compared with users of NRT. On the contrary, some events were associated with a reduced 
risk (i.e., heart failure and depression). Modelling the effects of any potential unmeasured 
confounders found that these would only lead to an increased risk associated with 
varenicline use under unlikely assumptions. 
 
We are not aware of previous studies specifically designed to assess the risks of varenicline 
or bupropion in patients with COPD. The efficacy trial by Tashkin et al. found higher rates of 
psychiatric adverse events (in particular sleep and mood disorders), but no difference in 
13 
 
serious adverse events between active varenicline and placebo.[28] However, this trial only 
included 504 smokers and was not statistically powered to detect rare events.  
 
More evidence on the risks of varenicline is available from studies conducted in the general 
smoking population. With regard to cardiovascular events, one meta-analysis reported an 
increased risk of cardiovascular events in users of varenicline,[24] whereas later meta-
analyses[7-9] and large-scale observational studies did not find such an association.[10, 11] 
With regard to neuropsychiatric events, a recent trial in 8,144 smokers with and without 
psychiatric disorders found no signiﬁcant increase in neuropsychiatric adverse events 
attributable to varenicline relative to nicotine patch or placebo.[29] Previous observational 
studies also did not find an association between varenicline use and neuropsychiatric risks. 
[11, 21, 22, 30, 31]    
 
The current study has several strengths and limitations. A study using observational data to 
compare the risks of different groups of medication users is prone to confounding by 
indication. Our data show indeed differences in patient characteristics between users of 
varenicline, bupropion and NRT. At baseline, the reference group of NRT users showed 
higher prevalence rates of risk factors for the adverse events under study (e.g., NRT users 
were older, had more severe COPD and higher prevalence of co-morbidities). We accounted 
for such differences by adjusting our regression models with measured confounders and by 
re-analysing the data in a propensity score analysis with trimming and matching. Uniquely, 
we also modelled what would need to be the distribution and influence of unmeasured 
confounders to overturn the key conclusions. We applied this approach, originally described 
by Lin et al.,[27] also in our previous analyses on the risks of varenicline in the general 
smoking population and described the implications in more detail.[11] In sum, we conclude 
that our findings are unlikely to be confounded to an extent that would have obscured an 
increased risk of varenicline.  
 
Another point to discuss is the use of routinely collected in the current study. Our definition 
of COPD relied on diagnostic codes entered by GPs into the patients' electronic health 
records. We combined codes for COPD diagnosis with codes for the measurement of 
spirometry and dyspnoea and excluded patients under the age of 35 to increase the validity 
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of our definition. However, we did not have individual patient data on lung function at the 
time of inclusion into our cohort. Hence, misclassification may have occurred, and a more 
fine-grained analysis according to different stages of COPD severity was not possible. 
Furthermore, this routine dataset did not include variables of potential interest, such as 
medication adherence, previous and current levels of tobacco exposure, and smoking 
cessation outcomes during follow-up. We were also not able to assess what the FDA has 
described as "nuanced" neuropsychiatric symptoms such as mood disorders that involve 
aggression.[32] Nevertheless, the neuropsychiatric events in our current study are among 
the most important ones and are included in the boxed warning. Finally, the sample size for 
the statistical analyses with bupropion was rather low as only 350 COPD patients had used 
this medication, which resulted in large confidence intervals around the hazard ratios for 
some events. For those adverse events, estimated values from the statistical models may 
not reflect efficient and generalisable results. 
 
A major strength of the current work is that we conducted the first, large-scale study on this 
topic in this patient population, with a sample size that included 3,574 COPD patients using 
varenicline (and 14,350 COPD patients in total). Second, we investigated the most important 
neuropsychiatric and cardiovascular adverse events at the same time and with the same 
methodology. Third, our study has high external validity due to the use of real-life patient 
data collected from a large number of different GP practices across England (a country with 
a national healthcare system in which all members of the community, regardless of 
socioeconomic status, have free and ready access to smoking cessation treatment). Finally, 
we planned our study methodology and described it in great detail prior to the analysis and 
interpretation of data in a peer-reviewed protocol.[18]  
 
We conclude that, in smokers with COPD, varenicline and bupropion are unlikely to be 
associated with increased risk of serious adverse neuropsychiatric or cardiovascular events 
compared with NRT.  
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Figure 1: Flow chart 
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Table 1: Characteristics of the subgroups of patients with (current study population) and 
without COPD at entry date to the cohort 
 COPD 
N=14,350 
No COPD 
N=150,416 
Age, mean (SD) 54.70 (9.59) 38.15 (12.31) 
Female sex 7,377 (51.41) 75,826 (50.41) 
Socio-economic status†, mean (SD) 3.25 (1.35) 3.09 (1.35) 
Diabetes 1,508 (10.51) 8,647 (5.75) 
Peptic ulcer disease 1,078 (7.51) 3,635 (2.42) 
Renal disease 1,227 (8.55) 5,018 (3.34) 
Rheumatological disease 888 (6.19) 3,278 (2.18) 
Cancer 1,249 (8.70) 4,670 (3.10) 
Alcohol misuse 1,431 (9.97) 10,535 (7.00) 
Prior ischaemic heart disease 2,018 (14.06) 6,046 (4.02) 
Prior cerebral infarctionstroke 1,073 (7.48) 3,353 (2.23) 
Prior heart failure 388 (2.70) 671 (0.45) 
Prior peripheral vascular disease 531 (3.70) 1,277 (0.85) 
Prior arrhythmia  742 (5.17) 2,337 (1.55) 
Prior depression 5,545 (38.64) 53,167 (35.35) 
Prior self-harm 1,563 (10.89) 15,711 (10.45) 
Data are presented as N (percentage within drug group) unless stated otherwise. NRT = nicotine replacement therapy. 
†Townsend Index: 1 (lowest) to 5 (highest level of deprivation).[25] 
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Table 2: Characteristics of COPD patients at entry date to the cohort, stratified by 
medication group  
 NRT 
N=10,426  
Bupropion 
N=350 
Varenicline  
N=3,574 
Age, mean (SD) 55.53 (9.72) 52.42 (9.31) 52.48 (8.82) 
Female sex 5,390 (51.70) 165 (47.14)  1,822 (50.98) 
MRC‡ score, mean (SD) 2.37 (1.02) 2.22 (0.96) 2.23 (0.98) 
Socio-economic status†, mean (SD) 3.28 (1.35) 3.14 (1.31) 3.20 (1.37) 
Diabetes  1,163 (11.15)  20 (5.71) 325 (9.09) 
Peptic ulcer disease  819 (7.85)   23 (6.57)    236 (6.60)  
Renal disease 979 (9.38)   14 (4.00)  234 (6.55)  
Rheumatological disease  679 (6.51)    13 (3.71)   196 (5.48)  
Cancer  943 (9.04)    29 (8.29)   277 (7.75)  
Alcohol misuse  1,112 (10.67)   22 (6.29)  297 (8.31) 
Prior ischaemic heart disease  1,556 (14.92) 32 (9.14)  430 (12.03) 
Prior cerebral infarctionstroke  829 (7.95)  22 (6.29)  222 (6.21) 
Prior heart failure  315 (3.02)  5 (1.43) 68 (1.90) 
Prior peripheral vascular disease 416 (3.99)  6 (1.71) 109 (3.05) 
Prior arrhythmia   603 (5.78)  13 (3.71)  126 (3.53) 
Prior depression  4,149 (39.79)   132 (37.71) 1,264 (35.37) 
Prior self-harm 1,174 (11.26)  32 (9.14) 357 (9.99) 
Data are presented as N (percentage within drug group) unless stated otherwise. NRT = nicotine replacement therapy. 
‡Medical Research Council dyspnoea score: 1 (lowest) to 5 (highest level of dyspnoea).[20] †Townsend Index: 1 (lowest) to 
5 (highest level of deprivation).[25] 
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Table 3: Incidence rates of events and hazard ratios (95%CI) of medication groups for all events during 6 months follow-up 
Event Patient-years Number of events Incidence of event per 
1,000 patient-years  
Hazard ratio (95% CI) 
 Crude Adjusted* 
Ischaemic heart disease 
 NRT 
 Bupropion 
 Varenicline 
 
5,061 
172 
1,756 
 
417 
11 
128 
 
82.4 
64.0 
72.9 
 
1 
0.78 (0.43-1.42) 
0.89 (0.73-1.08) 
 
1 
1.18 (0.64-2.15) 
1.02 (0.83-1.24) 
Cerebral infarctionStroke 
 NRT 
 Bupropion 
 Varenicline 
 
5,140 
175 
1,780 
 
155 
3 
34 
 
30.2 
17.1 
19.1 
 
1 
0.57 (0.18-1.79) 
0.63 (0.44-0.92) 
 
1 
0.62 (0.20-1.96) 
0.76 (0.52-1.11) 
Heart failure 
 NRT 
 Bupropion 
 Varenicline 
 
5,148 
175 
1,783 
 
118 
1 
18 
 
22.9 
5.7 
10.1 
 
1 
0.25 (0.03-1.79) 
0.44 (0.27-0.72) 
 
1 
0.40 (0.06-2.89) 
0.56 (0.34-0.92) 
Peripheral vascular disease 
 NRT 
 Bupropion 
 Varenicline 
 
5,156 
175 
1,784 
 
93 
1 
17 
 
18.0 
5.7 
9.5 
 
1 
0.32 (0.04-2.28) 
0.53 (0.32-0.89) 
 
1 
0.49 (0.07-3.56) 
0.62 (0.37-1.05) 
Arrhythmia  
 NRT 
 Bupropion 
 Varenicline 
 
5,134 
174 
1,777 
 
174 
4 
38 
 
33.9 
23.0 
21.4 
 
1 
0.68 (0.25-1.83) 
0.63 (0.44-0.90) 
 
1 
0.92 (0.34-2.50) 
0.84 (0.59-1.20) 
Depression  
 NRT 
 Bupropion 
 Varenicline 
 
4,989 
171 
1,745 
 
686 
17 
167 
 
137.5 
99.4 
95.7 
 
1 
0.72 (0.45-1.17) 
0.70 (0.59-0.83) 
 
1 
0.73 (0.45-1.18) 
0.73 (0.61-0.86) 
Self-harm 
 NRT 
 Bupropion 
 Varenicline 
 
5,174 
175 
1,786 
 
36 
1 
9 
 
7.0 
5.7 
5.0 
 
1 
0.82 (0.12-6.00) 
0.72 (0.35-1.51) 
 
1 
0.90 (0.12-6.58) 
0.78 (0.37-1.63) 
NRT = nicotine replacement therapy. *Adjusted for age, sex, socio-economic status, Medical Research Council dyspnoea score, Strategic Health Authority of the general practice, 
comorbidities (i.e., prior recordings of COPD, diabetes, peptic ulcer disease, renal disease, rheumatological disease, or cancer), alcohol misuse, and any recordings of the neuropsychiatric and 
cardiovascular events of interest that occurred prior to the patient's entry date to the cohort.  
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Table 4: Hazard ratios (95%CI) of events during 6 months follow-up in the propensity score 
matched samples 
Event Hazard ratio (95% CI) 
Bupropion vs. NRT  
(N=682) 
Varenicline vs. NRT  
(N=6,968)  
Ischaemic heart disease 1.23 (0.49-3.12) 0.97 (0.75-1.24) 
Cerebral infarctionStroke 0.49 (0.12-1.95) 1.06 (0.65-1.75) 
Heart failure 0.99 (0.06-15.89) 0.77 (0.41-1.45) 
Peripheral vascular disease 0.99 (0.06-15.80) 0.57 (0.31-1.05) 
Arrhythmia  3.96 (0.44-35.41) 1.12 (0.70-1.81) 
Depression 0.75 (0.40-1.41) 0.68 (0.55-0.83) 
Self-harm 0.49 (0.04-5.43) 0.60 (0.26-1.37) 
NRT = nicotine replacement therapy.  
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Table 5: Hazard ratio (95%CI) for self-harm during 6 months follow-up in users of varenicline vs. NRT, adjusted for an unmeasured binary 
confounder with a hazard ratio of 3 
 P0 
P1 
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 
0.0 
0.78 
 (0.37, 1.63) 
0.94 
 (0.44, 1.96) 
1.09 
 (0.52, 2.28) 
1.25 
 (0.59, 2.61) 
1.4 
 (0.67, 2.93) 
1.56 
 (0.74, 3.26) 
1.72 
 (0.81, 3.59) 
1.87 
 (0.89, 3.91) 
2.03 
 (0.96, 4.24) 
2.18 
 (1.04, 4.56) 
2.34 
 (1.11, 4.89) 
0.1 
0.65 
 (0.31, 1.36) 
0.78 
 (0.37, 1.63) 
0.91 
 (0.43, 1.9) 
1.04 
 (0.49, 2.17) 
1.17 
 (0.56, 2.45) 
1.3 
 (0.62, 2.72) 
1.43 
 (0.68, 2.99) 
1.56 
 (0.74, 3.26) 
1.69 
 (0.8, 3.53) 
1.82 
 (0.86, 3.8) 
1.95 
 (0.93, 4.08) 
0.2 
0.56 
 (0.26, 1.16) 
0.67 
 (0.32, 1.4) 
0.78 
 (0.37, 1.63) 
0.89 
 (0.42, 1.86) 
1 
 (0.48, 2.1) 
1.11 
 (0.53, 2.33) 
1.23 
 (0.58, 2.56) 
1.34 
 (0.63, 2.79) 
1.45 
 (0.69, 3.03) 
1.56 
 (0.74, 3.26) 
1.67 
 (0.79, 3.49) 
0.3 
0.49 
 (0.23, 1.02) 
0.59 
 (0.28, 1.22) 
0.68 
 (0.32, 1.43) 
0.78 
 (0.37, 1.63) 
0.88 
 (0.42, 1.83) 
0.98 
 (0.46, 2.04) 
1.07 
 (0.51, 2.24) 
1.17 
 (0.56, 2.45) 
1.27 
 (0.6, 2.65) 
1.37 
 (0.65, 2.85) 
1.46 
 (0.69, 3.06) 
0.4 
0.43 
 (0.21, 0.91) 
0.52 
 (0.25, 1.09) 
0.61 
 (0.29, 1.27) 
0.69 
 (0.33, 1.45) 
0.78 
 (0.37, 1.63) 
0.87 
 (0.41, 1.81) 
0.95 
 (0.45, 1.99) 
1.04 
 (0.49, 2.17) 
1.13 
 (0.53, 2.35) 
1.21 
 (0.58, 2.54) 
1.3 
 (0.62, 2.72) 
0.5 
0.39 
 (0.19, 0.82) 
0.47 
 (0.22, 0.98) 
0.55 
 (0.26, 1.14) 
0.62 
 (0.3, 1.3) 
0.7 
 (0.33, 1.47) 
0.78 
 (0.37, 1.63) 
0.86 
 (0.41, 1.79) 
0.94 
 (0.44, 1.96) 
1.01 
 (0.48, 2.12) 
1.09 
 (0.52, 2.28) 
1.17 
 (0.56, 2.45) 
0.6 
0.35 
 (0.17, 0.74) 
0.43 
 (0.2, 0.89) 
0.5 
 (0.24, 1.04) 
0.57 
 (0.27, 1.19) 
0.64 
 (0.3, 1.33) 
0.71 
 (0.34, 1.48) 
0.78 
 (0.37, 1.63) 
0.85 
 (0.4, 1.78) 
0.92 
 (0.44, 1.93) 
0.99 
 (0.47, 2.07) 
1.06 
 (0.5, 2.22) 
0.7 
0.33 
 (0.15, 0.68) 
0.39 
 (0.19, 0.82) 
0.46 
 (0.22, 0.95) 
0.52 
 (0.25, 1.09) 
0.59 
 (0.28, 1.22) 
0.65 
 (0.31, 1.36) 
0.72 
 (0.34, 1.49) 
0.78 
 (0.37, 1.63) 
0.85 
 (0.4, 1.77) 
0.91 
 (0.43, 1.9) 
0.98 
 (0.46, 2.04) 
0.8 
0.3 
 (0.14, 0.63) 
0.36 
 (0.17, 0.75) 
0.42 
 (0.2, 0.88) 
0.48 
 (0.23, 1) 
0.54 
 (0.26, 1.13) 
0.6 
 (0.28, 1.25) 
0.66 
 (0.31, 1.38) 
0.72 
 (0.34, 1.5) 
0.78 
 (0.37, 1.63) 
0.84 
 (0.4, 1.76) 
0.9 
 (0.43, 1.88) 
0.9 
0.28 
 (0.13, 0.58) 
0.33 
 (0.16, 0.7) 
0.39 
 (0.19, 0.82) 
0.45 
 (0.21, 0.93) 
0.5 
 (0.24, 1.05) 
0.56 
 (0.26, 1.16) 
0.61 
 (0.29, 1.28) 
0.67 
 (0.32, 1.4) 
0.72 
 (0.34, 1.51) 
0.78 
 (0.37, 1.63) 
0.84 
 (0.4, 1.75) 
1.0 
0.26 
 (0.12, 0.54) 
0.31 
 (0.15, 0.65) 
0.36 
 (0.17, 0.76) 
0.42 
 (0.2, 0.87) 
0.47 
 (0.22, 0.98) 
0.52 
 (0.25, 1.09) 
0.57 
 (0.27, 1.2) 
0.62 
 (0.3, 1.3) 
0.68 
 (0.32, 1.41) 
0.73 
 (0.35, 1.52) 
0.78 
 (0.37, 1.63) 
This tables shows how the observed hazard ratio (diagonal line of cells with dotted border) would change in the presence of an unmeasured confounder with a hazard ratio of three and 
different combinations of prevalence rates among the user groups. P1/P0 = prevalence of the unmeasured confounder among users of varenicline (P1) and NRT (P0). The cells filled with grey 
mark the situations in which varenicline would be associated with a statistically significant increased hazard of the event. These calculations are based on: Lin et al. Biometrics 1998, 54(3), 
948-963 (equation 2.9). 
 
